Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Item

http://www.wikidata.org/entity/Q34057425

Q34057425

about

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections Antibiotics in the clinical pipeline at the end of 2015.Advances in Intra-abdominal Sepsis: What Is New?Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Ceftolozane/Tazobactam.Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy.Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Novel antibiotics: are we still in the pre-post-antibiotic era?Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Antimicrobial Resistance in the Intensive Care Unit: A Focus on Gram-Negative Bacterial Infections.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Optimal Treatment for Complicated Intra-abdominal Infections in the Era of Antibiotic Resistance: A Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Therapy With Metronidazole [New antibiotics prior to approval: is this the end of the innovative stagnation?].Antimicrobial agents - optimising the ecological balance.The efficacy of combined therapy with metronidazole and broad-spectrum antibiotics on postoperative outcomes for pediatric patients with perforated appendicitis.In Vitro Activity of Ceftazidime-Avibactam Against Isolates from Patients in a Phase 3 Clinical Trial for the Treatment of Complicated Intra-Abdominal Infections.Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?

P2860

Q21146707-E528EA68-18C6-4EE6-9582-BDE9A19F1268 Q26747429-8BDD2B29-F440-447C-AA66-78E699CE1AA1 Q26995305-DEA854E3-28D9-483C-8C81-F1B376C501A0 Q27001490-62737F74-0B2B-4F1B-9BB0-CCB9ACBF76C3 Q28069563-275BABBC-5768-4649-9CEE-349D34928B21 Q30249262-2074A67B-2CCC-4162-988D-33ED7077B6D6 Q30279142-0D3D1C23-3842-4524-BB75-151B80653DF0 Q35004269-BD055AA5-3671-4696-A121-C7C797371B35 Q35545954-297DEA99-4364-43B9-884D-EEEEF0F0F98D Q36055019-BE80CFC1-5DF2-44C3-8838-E8C90022D994 Q36355345-D88D09B8-CE34-4990-BA5F-606F1BA9A328 Q36438924-8C1BE205-E1D9-452A-AC6B-A0A0EA4357FC Q36915096-3D30AB86-8020-4BF7-90E4-DC214ADADD7E Q37055016-3DB880D0-425C-4A14-B964-93B0586B1FCA Q37308807-7AC5C967-F985-41F1-8047-06D95E642D10 Q38296151-3F1A1356-5D4C-400C-BEE1-E72A5AAB3612 Q38363223-5244ECD3-3A08-41B7-95FD-5DD75D91EF78 Q38541624-65141F92-ADC1-45FD-83C3-1D66B46323B9 Q38544744-3E6411D4-DF59-44BC-9CFE-E532D462FF19 Q38648594-A19CB8C3-2266-43DA-9377-158EA60E1D18 Q38650049-F89CF63F-9F37-4B0B-80E2-1321FE17E07B Q38690748-7D8EBDE7-92A7-4872-B4C4-9D0A03380054 Q38697988-DC337FF4-D86F-46D0-AC60-BB1AE5374552 Q38864569-23BEED92-C846-4A85-86CA-5290AA8BF99F Q38934400-2DD41E81-D60A-438D-BF49-0320981A9C4E Q38972381-60754116-BCCA-4E39-9913-17DB297EFA57 Q41675300-07C4CAEE-5227-4C81-AA4F-BE58E6DC56B6 Q42376673-D55A494E-29D5-44F1-A8AA-8034D4731DF8 Q47095071-3FC580E4-91A8-4E39-ACAA-6C00EB339F6C Q52568634-9551FC60-6D21-416D-9C84-BC1DAE995CEE Q58694612-D50061CC-5470-4D28-B86A-875052B7FA97

P2860

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Item

http://www.wikidata.org/entity/Q34057425

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu